We Offer Worldwide Shipping
Login Wishlist

Tanshinone I

$78

  • Brand : BIOFRON

  • Catalogue Number : BF-T3007

  • Specification : 98%

  • CAS number : 568-73-0

  • Formula : C18H12O3

  • Molecular Weight : 276.29

  • PUBCHEM ID : 114917

  • Volume : 25mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-T3007

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

276.29

Appearance

Dark red crystals

Botanical Source

Salvia miltiorrhiza

Structure Type

Terpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC1=C2C=CC3=C(C2=CC=C1)C(=O)C(=O)C4=C3OC=C4C

Synonyms

Salvia quinone/Phenanthro[1,2-b]furan-10,11-dione, 1,6-dimethyl-/Tanshinone/Tanshinon I/tanshinone-I/Tanshinone 1/1,6-Dimethylphenanthro[1,2-b]furan-10,11-dione/TANSHINONES IIA/Tanshinquinone I/Tanshine I

IUPAC Name

1,6-dimethylnaphtho[1,2-g][1]benzofuran-10,11-dione

Density

1.3±0.1 g/cm3

Solubility

Methanol; DMF

Flash Point

245.9±15.6 °C

Boiling Point

498.0±24.0 °C at 760 mmHg

Melting Point

233-234ºC

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2932990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:568-73-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

30878387

Abstract

Vascular smooth muscle cell (VSMC) proliferation plays a critical role in arterial remodeling during various vascular diseases including atherosclerosis and hypertension. Tanshinone I, a major component of Salvia miltiorrhiza, exerts protective effects against cardiovascular diseases. In this study, we investigated the effects of tanshinone I on VSMC proliferation, as well as the underlying mechanisms. We found that this compound inhibited the proliferation of VSMCs in a dose-dependent manner, based on 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and 5-ethynyl-2′-deoxyuridine (EdU) assays. Western blotting demonstrated that tanshinone I inhibited the expression of proliferation-related proteins, including cyclin-dependent kinase 4 (CDK4), cyclin D3, and cyclin D1, in a dose-dependent manner. Molecular docking showed that this compound docked to the inhibitor-binding site of the insulin-like growth factor 1 (IGF-1) receptor (IGF-1R), and the binding energy between tanshinone I and IGF-1R was -9.021 kcal/mol. Molecular dynamic simulations showed that the IGF-1R-tanshinone I binding was stable. We also found that tanshinone I dose-dependently inhibited IGF-1R activation and its downstream molecules, insulin receptor substrate (IRS)-1, phosphatidylinositol-3-Kinase (PI3K), Akt, glycogen synthase kinase-3 beta (GSK3β), mammalian target of rapamycin (mTOR), 70S6K, and ribosomal protein S6 (RPS6). Notably, activation of IGF-1R by recombinant IGF-1 rescued the activity of IGF-1R and its downstream molecules, and the proliferation of tanshinone I-treated VSMC. In addition, blocking PI3K signaling with LY294002 showed the important role of this pathway in tanshinone I-mediated suppression of VSMC proliferation. Collectively, these data demonstrated that tanshinone I might inhibit VSMC proliferation by inhibiting IGF-1R/PI3K signaling.

Copyright © 2019. Published by Elsevier B.V.

KEYWORDS

Akt; GSK3β; IGF-1R; PI3K; Proliferation; Tanshinone I; Vascular smooth muscle cell; mTOR

Title

Tanshinone I inhibits vascular smooth muscle cell proliferation by targeting insulin-like growth factor-1 receptor/phosphatidylinositol-3-kinase signaling pathway.

Author

Wu YT1, Bi YM1, Tan ZB1, Xie LP1, Xu HL1, Fan HJ1, Chen HM1, Li J1, Liu B2, Zhou YC3.

Publish date

2019 Jun 15

PMID

28443671

Abstract

A novel total synthesis of tanshinone I (1) via the intermediate 3-hydroxy-8-methyl-1,4-phenanthrenedione (8) is described. The low overall yields and the use of expensive reagents in the synthesis process were minimized by the use of the Diels-Alder reaction to directly construct the 1,4-phenanthrenedione scaffold, providing tanshinone I (1) in only three steps.

Title

Total Synthesis of Tanshinone I.

Author

Wu N1, Ma WC1, Mao SJ1, Wu Y1, Jin H1.

Publish date

2017 May 26

PMID

31293090

Abstract

Tanshinone I (Tan I) is a widely used diterpene compound derived from the traditional Chinese herb Danshen. Increasing evidence suggests that it exhibits anti-cancer activity in various human cancers. However, the in vitro and in vivo effects of Tan I on osteosarcoma (OS) remain inadequately elucidated, especially those against tumour metastasis. Our results showed that Tan I significantly inhibited OS cancer cell proliferation, migration and invasion and induced cell apoptosis in vitro. Moreover, treatment with 10 and 20 mg/kg Tan I effectively suppressed tumour growth in subcutaneous xenografts and orthotopic xenograft mouse models. In addition, Tan I significantly inhibited tumour metastasis in intracardiac inoculation xenograft models. The results also showed that Tan I-induced increased expression of the proapoptotic gene Bax and decreased expression of the anti-apoptotic gene Bcl-2 is the possible mechanism of its anti-cancer effects. Tan I was also found to abolish the IL-6-mediated activation of the JAK/STAT3 signalling pathway. Conclusively, this study is the first to show that Tan I suppresses OS growth and metastasis in vitro and in vivo, suggesting it may be a potential novel and efficient drug candidate for the treatment of OS progression.

© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

KEYWORDS

JAK/STAT3 signalling pathway; osteosarcoma; tanshinone I; tumour growth and metastasis

Title

Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway.

Author

Wang W1, Li J1, Ding Z1, Li Y1, Wang J1, Chen S1, Miao J1.

Publish date

2019 Sep


Description :

Tanshinone I is an inhibitor of type IIA human recombinant sPLA2 (IC50=11 μM) and rabbit recombinant cPLA2 (IC50=82 μM).